Explore our resources by research/diagnostic specialty or content type

ALPCO specialists are leveraging their extensive expertise to create a growing collection of resources for your research and testing. Find resources that benefit your work using the handy filters.

Diabetes & Obesity

GLP-1 Amide Elisa
March 20, 2024

Product Data: Active GLP-1 (7-36) amide Chemiluminescence ELISA

ALPCO’s Active GLP-1 (7-36) amide Chemiluminescence ELISA accurately measures the major biologically active circulating form of GLP-1.1,2 This well-characterized assay provides high analytical sensitivity, a short incubation time, and measures active GLP-1 (7-36) amide in fasted and fed samples.

Rodent Insulin Chemiluminescence ELISA
March 20, 2024

Product Data: Rodent Insulin Chemiluminescence ELISA

The STELLUX® Rodent Insulin ELISA provides the flexibility to run both mouse and rat samples on the same plate with minimal to no dilution and a short two hour incubation.

Insulin Chemiluminescence ELISA
March 19, 2024

Product Data: Insulin Chemiluminescence ELISA

ALPCO’s Insulin Chemiluminescence ELISA detects insulin at levels as low as 20 pg/mL in human serum, plasma, and β-islet tissue culture supernatants, without cross-reactivity to human intact proinsulin, mouse insulin, or rat insulin.

GLP-1 Amide Elisa
March 18, 2024

Product Data Package: Active GLP-1 (7-36) amide ELISA

ALPCO's STELLUX® Chemi Active GLP-1 (7-36) Amide ELISA provides accurate quantification and resolves sample size and analytical performance issues.

8 Questions to Ask Before Choosing an Allergy Testing Platform
November 21, 2023

Celebrating Diabetes Research

In honor of scientists and researchers in the field of diabetes, we've compiled a partial list of their 2023 published work. These publications aren't just studies; they're milestones on the path to a healthier future, made possible by their dedication. 

What makes this list so special to ALPCO? It's a testament to how our products empower these tireless champions in their quest for discoveries and breakthroughs in diabetes research. 

Vasopressin: An Important Biomarker for Water Metabolism & Sleep Research
April 21, 2023

Vasopressin: An Important Biomarker for Water Metabolism & Sleep Research

ALPCO is pleased to announce the addition of two new radioimmunoassays (RIA) to measure vasopressin. The Vasopressin RIA and the Vasopressin Direct RIA. Both assays were originally developed by BÜHLMANN Laboratories. After optimization for greater ease-of-use, they are now offered by NovoLytiX GmbH of Switzerland. ALPCO is proud to be the exclusive distributor for the Vasopressin RIA and Va...
Circadian Rhythm and Obesity: The Role of the Body’s Clocks in Metabolic Disorders
April 21, 2023

Circadian Rhythm and Obesity: The Role of the Body’s Clocks in Metabolic Disorders

800 million people worldwide struggle with obesity, a disease poised to cost over $1 trillion in medical consequences by 2025. Over 40% of the US population is impacted, according to the Centers for Disease Control. Obesity is a major risk factor in the development of illnesses that lead to diabetes, such as insulin resistance, hypertension, and other metabolic disorders. Long-term disrupti...
Diabetes and Obesity
April 21, 2023

Diabetes and Obesity

Diabetes and Obesity Learning Library! As a leading provider of testing solutions for the diabetes and obesity research community, we support scientists’ efforts to gain a greater understanding of these conditions. With no cure for type 1 or type 2 diabetes and a lack of effective obesity treatments, scientists in these fields are continually in need of new methods to advance their studies. As...
Honoring Scientific Advancements in the Discovery of Insulin
April 20, 2023

Honoring Scientific Advancements in the Discovery of Insulin

Celebrate Insulin’s Discovery: Download the History of Insulin Timeline for Your Lab! The year 2021 marked the 100th anniversary of Banting, Best, and Macleod discovery of insulin. However, many other scientists also contributed to the foundational understanding of endocrinology that enabled one of the most important medical ...

Incretins GIP and GLP-1 in Diabetes and Obesity
April 20, 2023

Incretins GIP and GLP-1 in Diabetes and Obesity

800 million people worldwide struggle with obesity, a disease which will cost over $1 trillion in medical consequences by 2025.  The CDC reports that severe obesity leads to life-altering and often life-threatening conditions like heart disease, stroke, type 2 diabetes, and certain cancers. What is the “Incretin Effect”? To help understand the mechanisms behind obesity and to develop trea...